FDA released long-awaited draft guidance Dec. 1 to help pave the way for the development of a fully closed-loop “artificial pancreas” device, which is poised to change the way patients manage type 1 diabetes by automating the process.
The draft outlines what information sponsors should include in investigational device exemption applications needed to begin U.S. clinical trials and...